Location:
Hyatt Regency Denver at the Colorado Convention Center
650 15th St
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room:
Capitol Ballroom 4-7 (Fourth Floor)
Schedule (MST):
5:30 PM – 6:00 PM – Registration and Dinner Buffet
6:00 PM – 8:00 PM – Educational Program
There is no registration fee for these events. However, preregistration is required as seating is limited.
Faculty:
Kelly EH Goodwin, MSN, RN, ANP-BC
Thoracic Cancer Center
Massachusetts General Hospital
Boston, Massachusetts
Melissa Johnson, MD
Associate Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee
Geoffrey R Oxnard, MD
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Mollie Reed, MSN, RN, ACNP-BC
Nurse Practitioner
Tennessee Oncology
Sarah Cannon Research Institute
Nashville, Tennessee
Moderator:
Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Novartis and Takeda Oncology (via educational grants) during the Oncology Nursing Society’s (ONS) 42nd Annual Congress, May 3-7, 2017 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
MODULE 1: Optimal Tumor Testing Algorithms; Management of Patients with Non-Small Cell Lung Cancer (NSCLC) and EGFR Activating Mutations
DISCUSSION TOPICS
- Incidence of lung cancer driver mutations and indications for mutational analysis
- Types of EGFR mutations and implications for first- and later-line treatment
- Comparative toxicities of the approved EGFR TKIs
- Relevance of T790M resistance mutations; use of plasma and urine mutation testing
- FDA approval of osimertinib and integration into nonprotocol treatment algorithms; available research data with and ongoing evaluation as first-line therapy
- Toxicity profile of osimertinib compared to first-generation EGFR TKIs
- Sequencing immune checkpoint inhibitors for patients with metastatic NSCLC and tumor mutations
MODULE 2: Existing and Emerging Therapeutic Options for Patients with ALK- and ROS1-Positive Disease
DISCUSSION TOPICS
- Efficacy of crizotinib in patients with ALK and ROS1 rearrangements; unique associated toxicities
- Available and emerging Phase III data with alectinib and ceritinib as first-line therapy for patients with ALK-positive disease
- Tolerability issues and dosing considerations with next-generation ALK inhibitors
- Variable CNS permeability with approved and investigational ALK inhibitors and implications for patients with ALK-positive brain metastases
MODULE 3: Other Potentially Targetable Tumor Mutations (BRAF V600E, HER2, RET, et cetera)
DISCUSSION TOPICS
- Current role of BRAF inhibitor therapy, with or without a MEK inhibitor, for BRAF V600E mutation-positive NSCLC
- Tolerability profile of combined BRAF/MEK inhibition
- Incidence of HER2 mutations and available data with HER2-targeted agents in NSCLC
- Preliminary efficacy and safety data with investigational targeted agents for RET-rearranged NSCLC
- Clinical significance of MET exon 14 skipping mutations and current role of crizotinib
MODULE 4: Clinical Approach to Patients with Metastatic Adenocarcinoma of the Lung without a Targetable Mutation
DISCUSSION TOPICS
- PD-L1 tumor proportion score (TPS) as a predictor of response to immune checkpoint inhibitor therapy
- Role of pembrolizumab as first-line therapy for patients with metastatic nonsquamous NSCLC and a PD-L1 TPS of 50% or greater
- Initial systemic treatment of metastatic nonsquamous NSCLC and a TPS of less than 50%: Choice of chemotherapy regimen and role of bevacizumab
- Rationale for and available clinical trial data supporting anti-PD-1/PD-L1 antibodies as second-line therapy for NSCLC
- Incidence and management of immune-related adverse events associated with checkpoint inhibitor therapy
- Available data with and potential role of anti-PD-1/PD-L1 antibodies in combination with chemotherapy
- Ongoing trials of anti-PD-1/PD-L1 antibodies in combination with other immunotherapeutic or systemic approaches
- Rational integration of ramucirumab into the management of nonsquamous NSCLC
MODULE 5: Treatment of Metastatic Squamous Cell Carcinoma of the Lung
DISCUSSION TOPICS
- Impact of histologic subtype (squamous versus nonsquamous) on the efficacy of pembrolizumab in newly diagnosed PD-L1-positive NSCLC
- First-line treatment of metastatic squamous cell NSCLC with a PD-L1 TPS of less than 50%: Available data with and current clinical role of nab paclitaxel
- Available research data with and patient selection for treatment with necitumumab
- Second-line treatment options for metastatic squamous cell NSCLC; consideration of prior treatment, symptomatology, et cetera
Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-small cell lung cancer (NSCLC).
Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:
- Communicate the clinical relevance of tumor histology and commonly identified genetic abnormalities to patients with NSCLC.
- Discuss the benefits and risks associated with systemic treatments used in the evidence-based treatment of metastatic NSCLC, including chemotherapeutic agents, targeted biologic therapies and novel immunotherapies.
- Educate patients about potential side effects associated with existing and recently approved therapies, and provide preventive strategies to reduce or ameliorate these toxicities.
- Assess research on the benefits of early palliative care for patients with metastatic NSCLC, and integrate this information, where appropriate, into patient consultations.
- Recall the scientific rationale for ongoing investigation of novel agents and therapeutic approaches in NSCLC, and counsel appropriately selected patients about study participation.
Accreditation Statements:
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 2 contact hours is provided by Research To Practice.
This activity is awarded 2 ANCC pharmacotherapeutic contact hours.
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity. Your certificate will be mailed to you within 4 to 6 weeks. International attendees, please note: In order for a certificate of completion to be issued, you must provide a valid email address.
ONCC/ILNA Certification Information:
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. Learners must apply for CNE credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2017/ILNA
Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.
Content Validation and Disclosures:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
Research To Practice staff and external reviewers — The scientific staff, planners, managers and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
Supporters:
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Novartis and Takeda Oncology.
Hyatt Regency Denver at the Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room:
Capitol Ballroom 4-7 (Fourth Floor)
The Hyatt Regency Denver at the Colorado Convention Center is the host hotel for the 2017 ONS Annual Congress.
Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 1 – NSCLC session. Onsite registration will be open starting at 5:15 PM (MST) on Wednesday, May 3rd.
If you are interested in standing by for seating (day of the program), please visit our registration desk located outside the Capitol Ballroom 4-7, on the fourth floor of the Hyatt Regency Denver at the Colorado Convention Center hotel (650 15th St, Denver, CO 80202). You may arrive up to 45-minutes before the program start time and receive a stand by ticket.
If seats become available for the program, we will accept stand by registrations on a first come, first served basis. Please note onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email atMeetings@ResearchToPractice.com or call (800) 233-6153.
|
